Abstract: A capacitor component includes a body including a dielectric layer and first and second internal electrode layers, and external electrodes disposed on the body and connected to the first and second internal electrode layers, respectively. The body includes an active portion in which the first and second internal electrode layers are alternately disposed with the dielectric layer interposed therebetween, a cover portion disposed on an upper portion and a lower portion of the active portion, and a side margin portion disposed on both sides of the active portion opposing each other. When a content of magnesium (Mg) included in the active portion is A1, a content of magnesium (Mg) included in the cover portion is C1, and a content of magnesium (Mg) included in the margin portion is M1, 0<A1<M1?C1 and A1/C1?0.60 are satisfied.

Abstract: A light emitting element may include a first semiconductor layer, an emission layer disposed on the first semiconductor layer, a second semiconductor layer disposed on the emission layer, an insulating film, and an electrode layer. The insulating film may enclose a side surface of the first semiconductor layer, a side surface of the emission layer, and a side surface of the second semiconductor layer. The electrode layer may be disposed on the second semiconductor layer and the insulating film. The insulating film may not enclose the electrode layer.

Abstract: Provided is a hybrid drive device including a main power source; an auxiliary power source; a main deformation part configured to be deformable in response to receiving a voltage from the main power source; and an auxiliary deformation part configured to connect to the main deformation part and to be deformable in response to receiving a voltage from the auxiliary power source.

Abstract: The present invention relates to a use of a pharmaceutical composition which includes a carbamate compound of chemical formula 1 and is administered to prevent, alleviate, or treat tremors or tremor syndrome.

Abstract: Provided is a hybrid drive device including a main power source; an auxiliary power source; a main deformation part configured to be deformable in response to receiving a voltage from the main power source; and an auxiliary deformation part configured to connect to the main deformation part and to be deformable in response to receiving a voltage from the auxiliary power source.

Abstract: The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, which comprises benzopyran derivatives substituted with secondary amines including imidazole or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention may be used in the form of eye drops.

Abstract: The present invention relates to a use of a pharmaceutical composition which includes a carbamate compound of chemical formula 1 and is administered to prevent, alleviate, or treat tremors or tremor syndrome.

Abstract: The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, which comprises benzopyran derivatives substituted with secondary amines including imidazole or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention may be used in the form of eye drops.

Abstract: Provided herein is a mutant microorganism containing a methylmalonyl-CoA reductase-encoding gene having an activity of converting methylmalonyl-CoA to methylmalonate semialdehyde and uses of the mutant microorganism. The mutant microorganism includes a gene encoding kingdom Archaea-derived methylmalonyl-CoA reductase.

Abstract: Provided is a glass composition for a ceramic phosphor plate, including: 75 to 85 mol % of an oxide mixture composed of SiO2, B2O3 and ZnO; 10 to 15 mol % of at least one carbonate compound including an alkali metal; and 1 to 5 mol % of Al2O3, wherein a content of B2O3 is less than 25 mol %.

Abstract: Provided are a novel derivative of 5-carbamoyl adamantan-2-yl amide of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutical use thereof for inhibiting the activity of 11?-hydroxystreroid dehydrogenase type 1 (11b-HSD1) or for preventing and/or treating various diseases mediated by 11?-hydroxystreroid dehydrogenase type 1.

Abstract: Provided is a glass composition for a ceramic phosphor plate, including: 75 to 85 mol % of an oxide mixture composed of SiO2, B2O3 and ZnO; 10 to 15 mol % of at least one carbonate compound including an alkali metal; and 1 to 5 mol % of Al2O3, wherein a content of B2O3 is less than 25 mol %.

Abstract: Provided are a novel derivative of 5-carbamoyl adamantan-2-yl amide or a pharmaceutically acceptable salt thereof, and a pharmaceutical use thereof for inhibiting the activity of 11?-hydroxystreroid dehydrogenase type 1 (11b-HSD1) or for preventing and/or treating various diseases mediated by 11?-hydroxystreroid dehydrogenase type 1.

Abstract: The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, which comprises benzopyran derivatives substituted with secondary amines including imidazole or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention may be used in the form of eye drops.

Abstract: The present invention relates to a composition for promoting memory or learning ability and to a composition for preventing and treating cognitive impairment, which comprise one, two or more plant extracts selected from the group consisting of Artemisia apiaceae extract, Illicium verum extract and Lepidium apefalum extract. The present invention has the effect of inhibiting neural cell damage, especially, neural cells of the basal part of the cerebrum by inhibiting acetylcholinesterase activity and through antioxidative activity (for example, inhibiting the generation of oxidative reactive species) and affinity for an NMDA receptor. The compositions of the present invention may have the effect of not only promoting memory or learning ability by protecting neural cells and preventing damage to neural cells but also of preventing and treating diseases caused by cognitive impairment.

Abstract: A method of fabricating a flash memory includes forming a first oxide film over a semiconductor substrate, forming a metal film over the first oxide film, forming a photoresist pattern on the metal film, etching the metal film using the photoresist pattern as a mask and forming a metal film pattern, forming a second oxide film overlying the metal film pattern, and heat-treating the first and second oxide films at high temperature and processing the metal film pattern using metal oxide crystallization.

Abstract: A method of fabricating a flash memory includes forming a first oxide film over a semiconductor substrate, forming a metal film over the first oxide film, forming a photoresist pattern on the metal film, etching the metal film using the photoresist pattern as a mask and forming a metal film pattern, forming a second oxide film including the metal film pattern, and heat-treating the first and second oxide films at high temperature and processing the metal film pattern using metal oxide crystallization.

Abstract: The present invention relates to a process for preparing haptens for immunoassay of phosphorothioate pesticides, which comprises the steps of reacting O-methyl(ethyl) dichlorothiophosphate with a phenolic compound to obtain O-methyl(ethyl) O-aryl chlorothiophosphate, and reacting the O-(methyl)ethyl O-aryl chlorothiophosphate thus obtained with aminocarboxylic acid to give desired haptens. In accordance with the present invention, haptens having a structure of O-methyl(ethyl) O-aryl N-(carboxyalkyl)phosphoramidothioate or O-methyl(ethyl) O-aryl N-alkyl-N-(carboxyalkyl)phosphoramidothioate can be simply prepared with a high yield by employing two-step processes in a cost-efficient manner.

Abstract: The present invention relates to a process for preparing haptens for immunoassay of phosphorothioate pesticides, which comprises the steps of reacting O-methyl(ethyl) dichlorothiophosphate with a phenolic compound to obtain O-methyl(ethyl) O-aryl chlorothiophosphate, and reacting the O-(methyl)ethyl O-aryl chlorothiophosphate thus obtained with aminocarboxylic acid to give desired haptens. In accordance with the present invention, haptens having a structure of O-methyl(ethyl) O-aryl, N-(carboxyalkyl)phosphoramidothioate or O-methyl(ethyl) O-aryl N-alkyl-N-(carboxyalkyl)phosphoramidothioate can be simply prepared with a high yield by employing two-step processes in a cost-efficient manner.